The Maturing Antibiotic Mantra: “Shorter Is Still Better”

Disclosure: This work was supported by the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, grant numbers R01 AI130060, R01 HSO25690, R01 AI1081719, and R21 AI127954. In the last 12 months, BS has consulted for Cempra, The Medicines Company, Medimmune, Tetraphase, AstraZeneca, Merck, Genentech, Forge, and Pfizer and owns equity in BioAIM, Synthetic Biologics, and Mycomed.